7 Therapeutic Game-Changers in 2019

Private equity acquisitions have increased rapidly across all aspects of healthcare, with gastroenterology practices experiencing the highest share. In the U.S., approximately 13% of gastroenterologists work in practices owned by private equity groups.

In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health.

According to the latest edition of The Cancer Atlas, lower-income nations are experiencing a rise in lung, colorectal and breast cancer incidence due to increasing adoption of behaviors associated with economic development—such as tobacco use, poor nutrition and physical inactivity.

In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.

Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, which offers a potential new strategy to treat aggressive cancers.

Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop working, and many patients relapse.